HIV combination regimen could lead to viral remission
AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The AELIX-003 trial evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7)… Read More